TherapeuticsMD (NASDAQ:TXMD) Now Covered by StockNews.com

Analysts at StockNews.com started coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a research note issued to investors on Saturday. The firm set a “hold” rating on the stock.

TherapeuticsMD Price Performance

TXMD opened at $1.66 on Friday. The stock’s fifty day moving average is $1.78 and its 200-day moving average is $2.04. TherapeuticsMD has a one year low of $1.43 and a one year high of $4.03.

TherapeuticsMD (NASDAQ:TXMD) last issued its quarterly earnings results on Monday, August 12th. The company reported ($0.09) earnings per share for the quarter. The business had revenue of $0.23 million for the quarter.

Institutional Investors Weigh In On TherapeuticsMD

A number of institutional investors and hedge funds have recently modified their holdings of TXMD. Clearline Capital LP boosted its holdings in shares of TherapeuticsMD by 18.9% in the second quarter. Clearline Capital LP now owns 636,622 shares of the company’s stock worth $1,025,000 after buying an additional 101,282 shares during the period. Prosperity Consulting Group LLC acquired a new position in TherapeuticsMD in the 1st quarter worth approximately $56,000. Finally, ADAR1 Capital Management LLC purchased a new position in TherapeuticsMD during the 4th quarter worth approximately $612,000. 30.74% of the stock is owned by institutional investors and hedge funds.

About TherapeuticsMD

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.